TORONTO, April 19 /PRNewswire-FirstCall/ - Spectral today announces a presentation documenting the efficacy of its proprietary RapidWN West Nile Virus IgM Test ("RAPIDWN(TM)"). This presentation is being made at the 39th Annual Oak Ridge Conference, entitled "Harnessing New Technology for Clinical Diagnostics".
The presentation outlines performance characteristics, as well as the safety and effectiveness, of the assay. Included in the data are results from studies at the National Microbiology Laboratory in Winnipeg, where Spectral's assay was found to correlate with the gold standard test, the Plaque Reduction and Neutralization (PRNT) assay, and 100 % of the time in acute cases of West Nile infection. The PRNT assay takes weeks to perform and requires specialized technicians and equipment. Spectral's assay gives results in less than thirty minutes and requires no special equipment or training.
"Dr. Nisar Shaikh, Vice President of Scientific Affairs at Spectral will be presenting this important data on the usefulness of our assay at this prestigious meeting," stated Dr. Paul Walker, President and CEO of Spectral. "Our test has been shown to be very effective in identifying patients with West Nile infection at an early stage, when therapeutic interventions can be used to potentially alter the incidence of adverse outcomes," he continued.
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Current products include Spectral's FDA approved rapid diagnostic for West Nile Virus (RapidWN(TM)) and its FDA approved rapid diagnostic for sepsis (EAA(TM)) as well as a range of other biological reagents. Spectral's common shares are listed on The Toronto Stock Exchange under the symbol SDI.
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
Spectral Diagnostics Inc.CONTACT: Spectral Diagnostics Inc., Dr. Paul Walker, Chief ExecutiveOfficer, (416) 626-3233
